论文部分内容阅读
目的探析行气健脾中药联合化疗治疗转移性三阴性乳腺癌患者临床疗效。方法:应用随机数字表法分为两组,对照组患者应用CEF方案化疗,治疗组患者应用行气健脾中药联合化疗,比较两组患者的临床疗效。结果:治疗前后两组中医症状评分比较,差异明显(P<0.01),且组间比较差异显著(P<0.01);近期疗效比较,治疗组84.4%,对照组78.8%,无显著性差异(P>0.05);两组患者生活质量改善比较,治疗组81.3%,对照组57.6%,差异显著(P<0.05);治疗组不良反应明显少于对照组(P<0.05);治疗组平均无进展生存期(PFS)为(0.84±1.02)个月,对照组平均无进展生存期(PFS)为(0.71±0.73)个月,差异无统计学意义(P>0.05)。结论:行气健脾中药联合化疗可改善患者化疗期间副作用,提高患者生存质量。
Objective To investigate the clinical effects of qi qi spleen combined with chemotherapy on patients with metastatic triple negative breast cancer. Methods: The random number table was divided into two groups. Patients in the control group were treated with CEF chemotherapy. Patients in the treatment group were treated with qiqi spleen combined with chemotherapy, and the clinical efficacy was compared between the two groups. Results: There was significant difference (P <0.01) between the two groups before and after treatment, and there was significant difference between the two groups (P <0.01). There was no significant difference between the two groups in curative effect (84.4% in the treatment group and 78.8% in the control group) P <0.05). The improvement of quality of life between the two groups was significant (81.3% vs 57.6%, P <0.05), and the adverse reactions in the treatment group were significantly less than those in the control group (P <0.05) The progression-free survival (PFS) was (0.84 ± 1.02) months. The mean progression-free survival (PFS) of the control group was (0.71 ± 0.73) months, with no significant difference (P> 0.05). Conclusion: The combination of qi spleen and qi combined with chemotherapy can improve side effects during chemotherapy and improve the quality of life of patients.